Amgen (AMGN) Cost of Revenue (2009 - 2026)

Amgen's Cost of Revenue history runs 18 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

• In Q1 2026, Cost of Revenue fell 7.55% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at -$1.8 billion (down 119.67% YoY), while the FY2025 annual figure was $1.3 billion, down 89.8% from the prior year.
• Cost of Revenue was $2.7 billion for Q1 2026 at Amgen, up from -$7.7 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $3.2 billion in Q2 2024 to a low of -$7.7 billion in Q4 2025.
• Historically, Cost of Revenue has averaged $1.3 billion across 5 years, with a median of $1.7 billion in 2022.
• Biggest YoY gain for Cost of Revenue was 4240.85% in 2025; the steepest drop was 349.0% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $1.7 billion in 2022, then jumped by 78.13% to $3.1 billion in 2023, then changed by 0.0% to $3.1 billion in 2024, then sank by 349.0% to -$7.7 billion in 2025, then jumped by 135.41% to $2.7 billion in 2026.
• The last three Cost of Revenue figures came in at $2.7 billion (Q1 2026), -$7.7 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.